BioCryst Pharmaceuticals, Inc. (BCRX) Stock

BioCryst Pharmaceuticals, Inc. (BCRX) is a Healthcare stock trading at $8.98 (as of 2026-06-18), with a market capitalization of $2.10B and a trailing P/E of -4.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

BioCryst Pharmaceuticals develops novel oral small-molecule medicines. It markets peramivir injection for acute uncomplicated influenza and ORLADEYO for hereditary angioedema, and is developing BCX9930, BCX9250, and Galidesivir for complement-mediated diseases, fibrodysplasia ossificans progressiva, and multiple RNA virus infections, respectively.

Valuation — source: SEC EDGAR (first-party)
Price$8.98
Market Cap$2.10B
P/E Ratio-4.9
EV / EBITDA-6.4
Price / Book-3.99
Price / Sales2.50
DCF Value (model)$23.78
DCF Upside vs Price164.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$874.84M
Net Margin30.2%
Return on Equity82.7%
Debt / Equity-0.71
Current Ratio1.91
Revenue Growth (YoY)94.1%
EPS Growth (YoY)-393.0%
FCF Growth (YoY)-749.0%
Financial Health — source: SEC EDGAR
Altman Z-Score2.41 (grey)
Piotroski F-Score7/9 (strong)
Valuation vs Sector & Industry
Stock P/E-4.9
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-123.5%
vs Industry-128.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($215.64M)
Institutional Holders Tracked10
Congressional Trades (recent)4
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCharles K. Gayer
Employees580
CountryUS
IPO Date1994-03-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Dianthus Therapeutics, Inc. (DNTH)
  • ANI Pharmaceuticals, Inc. (ANIP)
  • MannKind Corporation (MNKD)
  • Kodiak Sciences Inc. (KOD)
  • Capricor Therapeutics, Inc. (CAPR)
  • Trevi Therapeutics, Inc. (TRVI)
  • Alvotech (ALVO)
  • Agios Pharmaceuticals, Inc. (AGIO)
BCRX earnings history · BCRX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.